Back to Top

BCR-ABL

BCR-ABL inhibitor asciminib (ABL001) meets phase 3 primary endpoint in CML

Asciminib significantly improved the Molecular Response Rate at 24 wks vs bosutinib in previously treated CML (Novartis press release)

Subscribe to RSS - BCR-ABL